Population access to new vaccines in European countries

Highlights • Access time to new vaccines against three different viruses were quantified. • Decision-making frameworks for introducing new vaccination programs were examined. • Timelines and clarity on criteria used are important for effective decision-making. • This is an attempt to explore varianc...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2013-06, Vol.31 (27), p.2862-2867
Main Authors: Blank, Patricia R, Schwenkglenks, Matthias, Sardos, Christelle Saint, Patris, Julien, Szucs, Thomas D
Format: Article
Language:English
Subjects:
Allergy and Immunology
Applied microbiology
Biological and medical sciences
Combined vaccines
confidence interval
correlation
Correlation analysis
Correlation coefficient
cross-sectional studies
Decision making
Decision Making, Organizational
Disease
Europe
Fundamental and applied biological sciences. Psychology
funding
Health Policy
Human papillomavirus
Humans
Immunization
Immunization Programs - economics
industry
issues and policy
marketing
Marketing approval
Marketing authorization
Microbiology
Papillomavirus Vaccines - economics
Pneumococcal Vaccines - economics
Population
Population access
Productivity
Public health
Regulation
Regulatory approval
Retrospective Studies
Rotavirus Vaccines - economics
Studies
surveys
Vaccination
Vaccine
Vaccines
Vaccines - economics
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Access time to new vaccines against three different viruses were quantified. • Decision-making frameworks for introducing new vaccination programs were examined. • Timelines and clarity on criteria used are important for effective decision-making. • This is an attempt to explore variances in population access to new vaccinations.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2013.04.039